Kiora Pharmaceuticals Inc Total Liabilities
Kiora Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Kiora Pharmaceuticals Inc (KPRX) has total liabilities worth $6.92 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Kiora Pharmaceuticals Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Kiora Pharmaceuticals Inc (2012–2025)
Total liabilities of Kiora Pharmaceuticals Inc from 2012 to 2025. This chart illustrates how Kiora Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Kiora Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Kiora Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Charan Insurance Public Company Limited
BK:CHARAN
|
Thailand | ฿321.06 Million |
|
Modern Internasional Tbk
JK:MDRN
|
Indonesia | Rp415.74 Billion |
|
Ihlas Yayin Holding A.S.
IS:IHYAY
|
Turkey | TL2.77 Billion |
|
STO Co. Ltd
KQ:098660
|
Korea | ₩54.54 Billion |
|
THG Holdings PLC
LSE:THG
|
UK | GBX1.11 Billion |
|
Humax Holdings Co. Ltd
KQ:028080
|
Korea | ₩337.08 Billion |
|
Equity Story Group Ltd
AU:EQS
|
Australia | AU$2.69 Million |
|
Sanwil Holding SA
WAR:SNW
|
Poland | zł16.81 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Kiora Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Kiora Pharmaceuticals Inc total assets.
Liquidity & Leverage Metrics
Kiora Pharmaceuticals Inc Total Liabilities Ratios Explained
Kiora Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kiora Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kiora Pharmaceuticals Inc (2012–2025)
The table below shows the annual total liabilities of Kiora Pharmaceuticals Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $8.13 Million | -24.22% |
| 2024-12-31 | $10.72 Million | +41.07% |
| 2023-12-31 | $7.60 Million | +4.56% |
| 2022-12-31 | $7.27 Million | +30.97% |
| 2021-12-31 | $5.55 Million | -0.42% |
| 2020-12-31 | $5.57 Million | +59.72% |
| 2019-12-31 | $3.49 Million | -34.70% |
| 2018-12-31 | $5.34 Million | -67.08% |
| 2017-12-31 | $16.23 Million | +61.35% |
| 2016-12-31 | $10.06 Million | +194.07% |
| 2015-12-31 | $3.42 Million | -91.74% |
| 2014-12-31 | $41.43 Million | +6.29% |
| 2013-12-31 | $38.98 Million | +4.91% |
| 2012-12-31 | $37.16 Million | -- |
About Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also deve… Read more